TITLE:
Antibody-Coupled Drugs in HER2-Positive Gastric Cancer
AUTHORS:
Baofeng Liu, Yuanmei Dai, Xiaohui Shen, Xiangyang Tian
KEYWORDS:
Antibody-Coupled Drugs, HER2-Positive Gastric Cancer, Review
JOURNAL NAME:
Journal of Biosciences and Medicines,
Vol.11 No.7,
July
7,
2023
ABSTRACT: Antibody drug conjugates (ADCs) are a new class of drugs that combine chemosynthetic drugs with antibody drugs through a linker. Antibody drug conjugates combine the targeting characteristics of traditional antibody drugs with the cytotoxic characteristics of small molecule drugs, while reducing the side effects of both drugs, making them a kind of “biological missile” and representing a relatively new and evolving class of anti-cancer drugs. Antibody-coupled drugs are currently used in many solid tumors, and this article reviews the clinical application of antibody-coupled drugs in HER2-positive gastric cancer.